Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III.
mouth neoplasms
oral cavity cancer
radiotherapy
squamous cell carcinoma
staging
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
30
03
2018
accepted:
19
07
2018
pubmed:
19
2
2019
medline:
5
9
2020
entrez:
19
2
2019
Statut:
ppublish
Résumé
This article is about the eighth edition staging guidelines for upstaged patients with oral cavity squamous cell carcinoma (OCSCC) with >10 mm depth to pT3. This upstages some patients from stage I-II to stage III, a point at which patients are traditionally considered for postoperative radiation therapy (PORT). The role of PORT in patients upstaged for >10 mm depth is unknown. We identified patients with surgically resected stage I-II OCSCC with >10 mm depth who were upstaged to stage III. We used Cox proportional hazard modeling to compare patients who received PORT to those who did not (median follow-up 38.6 months). We observed that 3.6% of patients with OCSCC were upstaged to stage III for depth >10 mm including 823 eligible patients. On adjusted analyses, PORT was associated with improved overall survival in patients upstaged to stage III (adjusted hazard ratio [aHR] 0.47, 95% confidence interval [CI] 0.30-0.73). PORT is associated with improved survival for patients with OCSCC upstaged to stage III for >10 mm depth.
Sections du résumé
BACKGROUND
This article is about the eighth edition staging guidelines for upstaged patients with oral cavity squamous cell carcinoma (OCSCC) with >10 mm depth to pT3. This upstages some patients from stage I-II to stage III, a point at which patients are traditionally considered for postoperative radiation therapy (PORT). The role of PORT in patients upstaged for >10 mm depth is unknown.
METHODS
We identified patients with surgically resected stage I-II OCSCC with >10 mm depth who were upstaged to stage III. We used Cox proportional hazard modeling to compare patients who received PORT to those who did not (median follow-up 38.6 months).
RESULTS
We observed that 3.6% of patients with OCSCC were upstaged to stage III for depth >10 mm including 823 eligible patients. On adjusted analyses, PORT was associated with improved overall survival in patients upstaged to stage III (adjusted hazard ratio [aHR] 0.47, 95% confidence interval [CI] 0.30-0.73).
CONCLUSION
PORT is associated with improved survival for patients with OCSCC upstaged to stage III for >10 mm depth.
Identifiants
pubmed: 30773733
doi: 10.1002/hed.25498
pmc: PMC6533633
mid: NIHMS1023882
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1178-1183Subventions
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097190
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
J Surg Oncol. 2002 Jul;80(3):119-20
pubmed: 12115792
Ann Surg Oncol. 2013 Jan;20(1):257-66
pubmed: 22872292
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
Radiat Oncol. 2010 May 27;5:43
pubmed: 20504371
Am J Surg. 1986 Oct;152(4):345-50
pubmed: 3766861
Cancer. 2009 Apr 1;115(7):1489-97
pubmed: 19197973
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Ann Surg. 1970 Nov;172(5):902-8
pubmed: 5477666
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1024-9
pubmed: 20610038
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
ANZ J Surg. 2016 May;86(5):366-71
pubmed: 26991038
Medicine (Baltimore). 2016 May;95(22):e3770
pubmed: 27258508
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1138-48
pubmed: 25075712